




- (51) **International Patent Classification:**
C12N 5/07 (2010.01) C12N 5/10 (2006.01)
- (21) **International Application Number:**
PCT/US2015/053252
- (22) **International Filing Date:**
30 September 2015 (30.09.2015)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/057,842 30 September 2014 (30.09.2014) US
62/057,847 30 September 2014 (30.09.2014) US
62/112,463 5 February 2015 (05.02.2015) US
62/135,345 19 March 2015 (19.03.2015) US
- (71) **Applicant:** AMICUS THERAPEUTICS, INC. [US/US];
1 Cedar Brook Drive, Cranbury, NJ 08512 (US).
- (72) **Inventors:** GOTSCHALL, Russell; 2065 Country Club
Drive, Doylestown, PA 18901 (US). DO, Hung; 819
Yearling Drive, New Hope, PA 18938 (US).
- (74) **Agents:** PEREIRA, Daniel, J. et al.; Oblon, McClelland,
Maier & Neustadt, L.L.P., 1940 Duke Street, Alexandria,
VA 22314 (US).

- (81) **Designated States** (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) **Title:** HIGHLY POTENT ACID ALPHA-GLUCOSIDASE WITH ENHANCED CARBOHYDRATES**Fig. 1A**Structure and Receptor Affinity for High Mannose and
Phosphorylated Oligosaccharides

(57) **Abstract:** Recombinant human alpha glucosidase (rhGAA) composition derived from CHO cells that contains a more optimized glycan composition consisting of a higher amount of rhGAA containing N-glycans carrying mannose-6-phosphate (M6P) or bis-M6P than conventional rhGAAs, along with low amount of non-phosphorylated high mannose glycans, and low amount of terminal galactose on complex oligosaccharides. Compositions containing the rhGAA, and methods of use are described.